...
首页> 外文期刊>journal of indian association of pediatric surgeons >Benign renal tumors in pediatric age group: Retrospective analysis
【24h】

Benign renal tumors in pediatric age group: Retrospective analysis

机译:Benign renal tumors in pediatric age group: Retrospective analysis

获取原文
           

摘要

© 2021 Wolters Kluwer Medknow Publications. All rights reserved.Background: Benign renal tumors are extremely rare and were studied here. This series also includes a renal teratoma in a horseshoe kidney, probably only the second in the pediatric literature. Materials and Methods: Retrospective review of children with benign renal tumors operated between 2006 and 2018 at one center. Results: Twelve patients (M:F ratio 10:2), age range 3 weeks (31-week gestation) to 13 years presented with large palpable renal swelling (n = 12) and hematuria (n = 3). Computed tomography (CT) scan showed features typical of the tumor. Final histopathology (age group mean) showed: multilocular cystic nephroma (MLCN)-n = 5 (41.7), (11-16 months 13.6); congenital mesoblastic nephroma (CMN)-n = 4 (33.3) (classic 1, cellular 3) (0.75-5 months 2.125); mature cystic teratoma-n = 1 (8.3): (48 months, in a horseshoe kidney), and angiomyolipoma (AML)-n = 2 (16.7) (144 months sporadic and 156 months tuberous sclerosis) One patient with cystic teratoma with no calcification on CT scan received pre-operative chemotherapy as fine-needle aspiration cytology (FNAC) reported malignant small blue cell tumor. Nephroureterectomy with Gerota's fascia could be done easily in all without intraoperative complications. Delay in presentation in MLCN and CMN led to increased symptoms and CT scan changes. All patients did well in 1.5-12 years (median 3 years) follow-up including cellular mesoblastic nephroma. Conclusions: Benign renal tumors often occur in specific age groups but may overlap that of Wilms tumor. Proper interpretation of clinical presentation, CT scan, and FNAC findings help in avoiding preoperative chemotherapy. Upfront nephroureterectomy is curative. Histopathological findings decide further treatment. Children with AML and tuberous sclerosis need lifelong follow-up.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号